Colitis ulcerosa
Zuletzt bearbeitet: Zuletzt revidiert:
Zuletzt revidiert von:Lino Witte
Definition:
Sich kontinuierlich, vom Rektum aus nach oral ausbreitende Entzündung der Kolonschleimhaut, die zu chronisch entzündlichen Darmerkrankungen gehört.
Häufigkeit:
Inzidenz von 3–4 auf 100.000 Personen in Deutschland.
Symptome:
Blutig-schleimige Diarrhöen mit Tenesmen und imperativem Stuhldrang.
Befunde:
Bauchschmerzen, häufig Zeichen der Mangelernährung mit Anämie, ggf. extraintestinale Manifestationen wie Arthralgien oder Erythema nodosum.
Diagnostik:
Anamnese, körperliche Untersuchung, Labor mit u. a. Calprotectin im Stuhl, Sonografie, Endoskopie mit Biopsien und histopathologischer Aufarbeitung.
Therapie:
Therapie der Wahl Mesalazin, im schweren Schub Steroide und ggf. Eskalation auf Immunmodulatoren, z. B. TNF-alpha-Blocker.
- Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). S3-Leitlinie Colitis ulcerosa. AWMF-Leitlinie Nr. 021-009, Stand 2021. register.awmf.org
- Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). S3-Leitlinie Kolorektales Karzinom. AWMF-Leitlinie Nr. 021-007OL, Stand 2017. register.awmf.org
- Basson MD. Ulcerative Colitis. Medscape, last updated Jul 26, 2019. emedicine.medscape.com
- Carter MJ, Lobo AJ, Travis SP, for the IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut 2004; 53 (suppl 5): 1-16. www.ncbi.nlm.nih.gov
- Langan RC, Gotsch PB, Krafczyk MA. Ulcerative colitis: Diagnosis and treatment. Am Fam Physician 2007; 76: 1323-30. PubMed
- Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). S3-Leitlinie Colitis ulcerosa. AWMF-Leitlinie Nr. 021-009, Stand 2021. register.awmf.org
- Silverberg MS, Satsangi J, Ahmad T, et al. Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19: 5-36. pubmed.ncbi.nlm.nih.gov
- Schroeder KW, Tremaine WJ, Ilstrup DM. Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative Colitis. NEJM 1987; 317: 1625-9. www.nejm.org
- Däbritz J, Gerner P, Enninger A, et al. Chronisch-entzündliche Darmerkrankungen bei Kindern und Jugendlichen. Dtsch Arztebl Int 2017; 114: 331-8. pubmed.ncbi.nlm.nih.gov
- Fischer S, Rath T, Neurath MF. Chronisch-entzündliche Darmerkrankungen Morbus Crohn und Colitis ulcerosa. Der Internist 2018; 59 : 681–693. doi.org
- Becker C, Neurath MF, Wirtz S. The Intestinal Microbiota in Inflammatory Bowel Disease. ILAR J 2015; 56(2): 192-204. pubmed.ncbi.nlm.nih.gov
- Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 417-29. PubMed
- Forrest K, Symmons D, Foster P. Systematic review: is ingestion of paracetamol or non-steroidal anti-inflammatory drugs associated with exacerbations of inflammatory bowel disease? Aliment Pharmacol Ther 2004; 20: 1035-43. PubMed
- Mahid SS,Minor KS,Soto RE, et al. Smoking and Inflammatory Bowel Disease: A Meta-Analysis. Mayo Clin Proc 2006; 81(11): 1462-71. pubmed.ncbi.nlm.nih.gov
- Rath HC, Schultz M, Freitag R, et al. Different subsets of enteric bacteria induce and perpetuate experimental colitis in rats and mice. Infect Immun 2001; 69: 2277-85. PubMed
- Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res 2008; 52: 867–874. pubmed.ncbi.nlm.nih.gov
- Frisch M, Pedersen BV, Andersson RE. Appendicitis, mesenteric lymphadenitis, and subsequent risk of ulcerative colitis: cohort studies in Sweden and Denmark. BMJ 2009; 338: b716. pubmed.ncbi.nlm.nih.gov
- Nayar M, Rhodes JM. Management of inflammatory bowel disease. Postgrad Med J 2004; 80: 206-13. PubMed
- Siegmund B. Pathogenese chronisch-entzündlicher Darmerkrankungen. Berlin, Heidelberg: Springer, 2020. link.springer.com
- Kornbluth A, Sachar DB, for the Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults (update): American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 2004; 99: 1371-85. PubMed
- Rothfuss KS, Stange EF, Herrlinger KR. Extraintestinal manifestations and complications in inflammatory bowel diseases. World J Gastroenterol 2006; 12: 4819-31. PubMed
- Ott C, Schölmerich J. Extraintestinal manifestations and complications in inflammatory bowel diseases. Nat Rev Gastroenterol Hepatol 2013; 10(10): 585-95. pubmed.ncbi.nlm.nih.gov
- van Rheenen PF, De Vijver EV, Fidler F. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010; 341: c3369. BMJ (DOI)
- Yang Z, Clark N, Park KT. Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children. Clin Gastroenterol Hepatol 2014; 12: 253-62. pmid:23883663 PubMed
- Turvill J. High negative predictive value of a normal faecal calprotectin in patients with symptomatic intestinal disease. Frontline Gastroenterology 2012; 3: 21-28. doi:10.1136/flgastro-2013-100429 www.ncbi.nlm.nih.gov
- Collins P, Rhodes J. Ulcerative colitis: diagnosis and management. BMJ 2006; 333: 340-3. PubMed
- Cima RR, Pemberton JH. Medical and surgical management of chronic ulcerative colitis. Arch Surg 2005; 140: 300-10. PubMed
- Whaley KG, Rosen MJ. Contemporary Medical Management of Acute Severe Ulcerative Colitis. Inflamm Bowel Dis 2019; 25(1): 56-66. pubmed.ncbi.nlm.nih.gov
- Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J 1955; 4947: 141-8. pubmed.ncbi.nlm.nih.gov
- Nielsen OH, Vainer B, Rask-Madsen J. Review article: the treatment of inflammatory bowel disease with 6-mercaptopurine or azathioprine. Aliment Pharmacol Ther 2001; 15: 1699-708. PubMed
- Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut 2002; 50: 485-9. www.ncbi.nlm.nih.gov
- Beaugerie L, Brousse N, Bouvier AM, et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 2009; 374: 1617-25. PubMed
- Fachinformation Azathioprin. Stand Juli 2016. Letzter Zugriff 24.05.2020. www.ratiopharm.de
- arznei-telegramm. ERHÖHTES KREBSRISIKO UNTER JAK-HEMMER TOFACITINIB (XELJANZ). a-t 2021; 52: 15-6. www.arznei-telegramm.de
- Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med 2019; 381(139): 1201-14. pubmed.ncbi.nlm.nih.gov
- Janssen. Fachinformation Stelara. Stand 2020. Letzter Zugriff 18.06.2021. static.janssen-emea.com
- Wang Y, MacDonald JK, Benchimol EI, et al. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database of Systematic Reviews 2015. doi:10.1002/14651858.CD006790.pub3 DOI
- Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Eng J Med 2005; 353: 2462-76. New England Journal of Medicine
- Jürgens M, Laubender RP, Hartl F. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis. Am J Gastroenterol 2010; 105: 1811-9. PubMed
- Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol 2013; 108 (8): 1268-76. pmid:23649185 PubMed
- Sands BE, Peyrin-Biroulet L, Lotfus EV, et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. NEJM 2019; 381: 1215-26. www.nejm.org
- Moayyedi P, Surette MG, Kim PT, et al. Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 2015; 149: 102-9. DOI:10.1053/j.gastro.2015.04.001 DOI
- Jahnsen J, Aadland E, Moum B, Schulz T, Sauar J, Lygren I, et al. Inflammatory bowel disease, disease course and status 5 years after diagnosis. Gastroenterology 2000; 118 (suppl 2): A118. www.gastrojournal.org
- Bach SP, Mortensen NJM. Revolution and evolution: 30 years of ileoanal pouch surgery. Inflamm Bowel Dis 2006; 12: 131-45. PubMed
- Gisbert JP, Gomollon F, Mate J, Pajares JM. Role of 5-aminosalicylic acid (5-ASA) in treatment of inflammatory bowel disease. A systematic review. Dig Dis Sci 2002; 47: 471 - 88. PubMed
- Klotz U. The role of aminosalicylates at the beginning of the new millenium in the treatment of chronic inflammatory bowel disease. Eur J Clin Pharmacol 2000; 56: 353 - 62. PubMed
- Allgayer H, Kruis W. Aminosalicylates: potential antineoplastic actions in colon cancer prevention. Scand J Gastroenterol 2002; 38: 125 - 31. PubMed
- Eaden J, Abrams K, Ekbom A, Jackson E, Mayberry J. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther 2000; 14: 145 - 53. PubMed
- Bernstein CN, Eaden J, Steinhart AH, Munkholm P, Gordon P. Cancer prevention in inflammatory bowel diseases and the chemoprophylatic potential of 5-aminosalicylic acid. Inflamm Bowel Dis 2002; 8: 356 - 61. PubMed
- Zhan YL, Zhan YA, Dai SX. Is a low FODMAP diet beneficial for patients with inflammatory bowel disease? A meta-analysis and systematic review. Clin Nutr. 2017. pmid:28587774 PubMed
- Langhorst J, Anthonisen IB, Steder-Neukamm U et al. Amount of systemic steroid medication is a strong predictor for the use of complementary and alternative medicine in patients with inflammatory bowel disease: results from a German national survey. Inflamm Bowel Dis 2005; 11: 287–295. pubmed.ncbi.nlm.nih.gov
- Torres J, Boyapati RK, Kennedy NA, et al. Systematic Review of Effects of Withdrawal of Immunomodulators or Biologic Agents From Patients With Inflammatory Bowel Disease. Gastroenterology 2015; 149: 1716-30. pmid:26381892 PubMed
- Moum B, Ekbom A, Vatn M, Elgjo K. Change in the extent of colonoscopic and histological involvement in ulcerative colitis over time. Am J Gastroenterol 1999; 94: 1564-9. PubMed
- Hovde Ø, Småstuen MC, Høivik ML, et al. Mortality and causes of death in ulcerative colitis: Results from 20 years of follow-up in the IBSEN study. Inflamm Bowel Dis 2016; 22(1):141-145. pubmed.ncbi.nlm.nih.gov
- Olsen KØ, Joelsson M, Laurberg S, et al. Fertility after ileal pouch-anal anastomosis in women with ulcerative colitis. Br J Surg 1999; 86: 493-5. PubMed
- Cvancarova M, Hovde O, Wanderaas M, et al. Do patients with longstanding IBD have higher cancer risk compared to the general population? Results from the IBSEN study. J Clin Oncol 2015; 33: Abstract 1573. www.researchgate.net
- Olén O, Erichsen R, Sachs MC, et al. Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study. Lancet 2020. pubmed.ncbi.nlm.nih.gov
- Collins PD, Mpofu C, Watson AJ, Rhodes JM. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev, issue 2, 2006. www.ncbi.nlm.nih.gov
- Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35. www.ncbi.nlm.nih.gov
- Sutherland LR. Maintenance therapy for inflammatory bowel disease: what really works. Can J Gastroenterol 1997; 11: 261-4. PubMed
- Kornbluth A, Marion JF, Salomon P, Janowitz HD. How effective is current medical therapy for severe ulcerative and Crohn's colitis? An analytic review of selected trials. J Clin Gastroenterol 1995; 20: 280-4. PubMed
- Turner D, Walsh CM, Steinhart AH, et al. Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression. Clin Gastroenterol Hepatol 2007; 5: 103-10. pubmed.ncbi.nlm.nih.gov
- D'Amico F, Bonovas S, Danese S, et al. Review article: faecal calprotectin and histologic remission in ulcerative colitis. Aliment Pharmacol Ther 2020; 51(7): 689-698. pubmed.ncbi.nlm.nih.gov
- Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS). S3-Leitlinie Kolorektales Karzinom. AWMF-Leitlinie Nr. 021-007OL, Stand 2017. register.awmf.org
- Lino Witte, Dr. med., Arzt in Weiterbildung Innere Medizin, Frankfurt